Axcella Announced Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical tria
Axcella Health: Q4 Earnings Insights
Axcella Health (NASDAQ:AXLA) reported its Q4 earnings results on Wednesday, March 30, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Axcella Health Q4 EPS $(0.46) Misses $(0.44) Estimate
Axcella Health (NASDAQ:AXLA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.44) by 4.55 percent. This is a 15 percent decrease over losses of $(0.40) per share from the
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Drug makers, Scientists Working For Long COVID Treatments: Reuters
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,
Axcella Health Earnings Conference Call Is Coming Up, Here’s What You Need To Know
Axcella Health (NASDAQ:AXLA) will host a conference call at 08:30 AM ET on March 30, 2022, to discuss Q4 2021 earnings results.
Executives Buy Around $16M Of 4 Penny Stocks
US stocks closed higher with the Nasdaq Composite jumping over 2% on Friday. Investors, meanwhile, focused on some notable insider trades
64 Biggest Movers From Yesterday
Gainers
Kidpik Corp. (NASDAQ: PIK) shares surged 158.2% to settle at $4.75 on Thursday after the company announced a partnership with The Walt Disney Co.